HomeCompareELEAF vs KMB

ELEAF vs KMB: Dividend Comparison 2026

ELEAF yields 1.55% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ELEAF wins by $22.41M in total portfolio value· pulled ahead in Year 4
10 years
ELEAF
ELEAF
● Live price
1.55%
Share price
$16.60
Annual div
$0.26
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.46M
Annual income
$19,980,387.57
Full ELEAF calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — ELEAF vs KMB

📍 ELEAF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELEAFKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELEAF + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELEAF pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELEAF
Annual income on $10K today (after 15% tax)
$131.82/yr
After 10yr DRIP, annual income (after tax)
$16,983,329.43/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, ELEAF beats the other by $16,978,899.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELEAF + KMB for your $10,000?

ELEAF: 50%KMB: 50%
100% KMB50/50100% ELEAF
Portfolio after 10yr
$11.25M
Annual income
$9,992,799.44/yr
Blended yield
88.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

ELEAF
No analyst data
Altman Z
5.7
Piotroski
3/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELEAF buys
0
KMB buys
0
No recent congressional trades found for ELEAF or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELEAFKMB
Forward yield1.55%5.25%
Annual dividend / share$0.26$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%17%
Portfolio after 10y$22.46M$45.9K
Annual income after 10y$19,980,387.57$5,211.33
Total dividends collected$22.24M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ELEAF vs KMB ($10,000, DRIP)

YearELEAF PortfolioELEAF Income/yrKMB PortfolioKMB Income/yrGap
1$11,010$310.16$11,314$613.68$304.00KMB
2$12,419$638.29$12,865$759.19$446.00KMB
3$14,634$1,345.75$14,709$943.96$75.00KMB
4← crossover$18,623$2,964.08$16,919$1,180.17+$1.7KELEAF
5$26,977$7,050.33$19,588$1,484.33+$7.4KELEAF
6$47,955$19,089.75$22,838$1,879.06+$25.1KELEAF
7$114,741$63,429.35$26,832$2,395.60+$87.9KELEAF
8$406,449$283,676.34$31,788$3,077.63+$374.7KELEAF
9$2,313,166$1,878,265.82$38,000$3,986.82+$2.28MELEAF
10$22,455,476$19,980,387.57$45,872$5,211.33+$22.41MELEAF

ELEAF vs KMB: Complete Analysis 2026

ELEAFStock

EL.En. S.p.A. engages in the research and development, manufacture, distribution, and sale of laser systems in Europe and internationally. The company offers medical laser equipment for use in the fields of physiotherapy, orthopedics, traumatology, rheumatology, dermatology, sports and rehabilitative medicines, surgery, aesthetics, and art; and laser sources and systems for cutting, welding, marking, and engraving on countless materials. It also provides laser sources that include liquid, solid, semiconductor, and gas; and after-sales services, such as supplying of spare parts, as well as consulting and technical assistance services. The company was founded in 1981 and is headquartered in Calenzano, Italy.

Full ELEAF Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this ELEAF vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELEAF vs SCHDELEAF vs JEPIELEAF vs OELEAF vs KOELEAF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.